-
CMS Coverage for PHP Telehealth Services Set to End After May 11
As the COVID-19 Public Health Emergency (PHE) draws to a close at the end of Thursday, May 11, the Centers for Medicare & Medicaid Services (CMS) has shared with NABH and other stakeholders the agency’s plans to end telehealth coverage for partial hospitalization program (PHP) services implemented during the PHE. In addition, CMS has explained that telehealth coverage will continue through December 2024 for Intensive Outpatient Program (IOP) services that qualify under the outpatient prospective payment system as “remote mental health services.” NABH continues to communicate with key Members of…
-
DEA Extends COVID-19 Telehealth Flexibilities for Prescription of Controlled Medications for Now
The U.S. Drug Enforcement Administration (DEA) on Wednesday said it will extend its COVID-19 telemedicine flexibilities for prescription of controlled medications as the agency works to determine how to move forward in a way that gives Americans access to needed medicine with the appropriate safeguards. An announcement from DEA noted the agency received a record number of comments on its proposed telemedicine rules, which prompted DEA and HHS to submit a draft temporary rule to the Office of Management and Budget requesting an extension. NABH submitted comments on this matter…
-
NABH Education & Research Foundation Webpage Now Features Grants & Funding Opportunities
The NABH Research and Education Foundation has updated its webpage with a section devoted to potential funding resources and opportunities for behavioral healthcare organizations and their employees. To access the Foundation’s webpage, visit NABH’s homepage and locate the “NABH Foundation” tab in the navigation menu. From there, hover over the tab to find a drop-down menu with the following sections: About, Grants & Funding Opportunities, Resources, and Contribute. We urge you to visit the page and search for potential funding opportunities, which NABH also includes in CEO Update, the association’s weekly e-newsletter.…
-
FDA Approves First Over-the-Counter Naloxone Spray
The U.S. Food and Drug Administration (FDA) today approved Narcan, 4 mg. naloxone hydrochloride nasal spray for over-the-counter (OTC), non-prescription use, making it the first naloxone product approved to use without a prescription. Naloxone is a medication that reverses the effects of opioid overdose rapidly and is the standard treatment for opioid overdose. The FDA’s action today clears the way for this life-saving medication to be sold directly to consumers in drug stores, convenience stores, grocery stores, gas stations, and online. The move comes at a time when the Centers…